Drugs / MUC1 100mer peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01720836 | Nov 2012 → Oct 2027 expected | non-small cell lung carcinoma | Olivera Finn | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC1 100mer peptide | “The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters...” NCT01720836 ↗ |
| Modality | Peptide | “MUC1 100mer peptide” NCT01720836 ↗ |
| Route | Subcutaneous | “All subjects will receive the vaccine subcutaneously every 3 weeks x 3” NCT01720836 ↗ |